GRI Bio Won Orphan Drug Status the Same Day MAIA Opened a Third Cancer Trial Site

GRI Bio’s stock is down 94% over the past year. On June 18, the FDA handed it seven years of potential market exclusivity. The same day, across the industry, a different small-cap was quietly opening its third US trial site for a lung cancer drug nobody outside biotech circles has heard of. Regulatory wins and stock charts keep moving on separate tracks this month.

GRI Bio Secures Orphan Drug Designation for GRI-0621 in Idiopathic Pulmonary Fibrosis

GRI Bio (Nasdaq: GRI) announced on June 18 that the FDA granted Orphan Drug Designation to GRI-0621 for idiopathic pulmonary fibrosis, a progressive, irreversible lung disease that affects tens of thousands of people in the US.

GRI-0621 is an oral, once-daily RARβ/γ-selective agonist, a compound that targets specific retinoic acid receptor subtypes thought to play a role in regulating immune-driven fibrosis. It was evaluated in a randomized, double-blind, placebo-controlled Phase 2a trial of 35 patients, roughly 80% of whom were also taking standard-of-care antifibrotics. The company reported the trial met its primary, secondary, and exploratory endpoints, with patients on GRI-0621 showing zero cough and 60% less treatment-related diarrhea than placebo despite higher background use of nintedanib in the active arm.

Orphan Drug Designation carries a potential pathway to seven years of US market exclusivity upon approval, tax credits on qualified clinical development costs, a waiver of certain FDA application fees, and closer regulatory engagement through development. None of that changes where the stock sits. GRI traded at $2.32 on the news, down 94% over the past year. A regulatory designation is a real asset. It is not a Phase 3 trial, and it is not revenue.

MAIA Biotechnology Opened a Third US Site for Its Lung Cancer Trial Expansion

MAIA Biotechnology (NYSE American: MAIA) announced on June 18 that Winship Cancer Institute of Emory University activated as the third US clinical site in its Phase 2 THIO-101 expansion trial, and is now enrolling patients. The trial studies ateganosine, MAIA’s lead telomere-targeting agent, a dual-action molecule designed to both interfere with telomere maintenance in cancer cells and increase tumor immunogenicity, as a third-line treatment for advanced non-small cell lung cancer.

This is the company’s third site activation in roughly two weeks. The FDA cleared an IND amendment on June 3 opening US enrollment for the trial expansion. A second US site opened at Central Alabama Research on June 10. The expansion trial now runs 44 active sites across six countries plus the three in the US. MAIA has said additional data from the expansion may support a potential accelerated approval filing. In parallel, the company is also screening for a separate pivotal Phase 3 trial of up to 300 patients comparing ateganosine plus a checkpoint inhibitor against investigator’s choice of chemotherapy.

MAIA traded around $1.30 this week, roughly in the middle of its 52-week range of $0.87 to $3.19. Adding clinical sites is operational momentum, not clinical proof. The expansion trial is still a Phase 2, and the accelerated approval pathway MAIA has flagged has not been confirmed by the FDA for this program.

GRI-0621 sNDA Pathway, MAIA Phase 3 Enrollment, and Ateganosine Accelerated Approval Discussion

GRI Bio: watch for any announcement of next steps toward a registrational program for GRI-0621 in IPF, and for updates on the company’s broader NKT agonist pipeline in lupus.

MAIA Biotechnology: watch enrollment pace across the now five active sites for the THIO-101 expansion, and for any formal FDA meeting outcome on the accelerated approval pathway the company has referenced.

Sources

Editorial Disclosure

This analysis is based entirely on publicly available information including company press releases sourced directly from company websites, SEC filings, and named wire services. Securities discussed include GRI Bio, Inc. (Nasdaq: GRI) and MAIA Biotechnology, Inc. (NYSE American: MAIA). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. GRI-0621 is an investigational therapy and has not been approved by the FDA for any indication; Orphan Drug Designation does not constitute approval and does not guarantee future approval. The Phase 2a trial referenced for GRI-0621 involved only 35 patients and, while randomized, double-blind, and placebo-controlled, results from a trial of this size carry inherent limitations in predicting outcomes in larger registrational studies. Ateganosine is an investigational therapy and has not been approved by the FDA for any indication. MAIA’s Phase 2 THIO-101 expansion trial is open-label without a placebo control arm at the sites referenced; the company’s statements regarding a potential accelerated approval filing reflect its own characterization and have not been confirmed as a defined regulatory pathway by the FDA. GRI Bio’s stock price decline of 94% over the trailing year and MAIA’s current trading position within its 52-week range are both noted for context; past price performance does not predict future results. All securities discussed carry significant investment risk including total loss of capital, and both companies are clinical-stage with no approved commercial products generating revenue. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.

GRI Bio Won Orphan Drug Status the Same Day MAIA Opened a Third Cancer Trial Site

Join our Mailing List